Elevation of an endogenous inhibitor of nitric oxide synthesis in experimental congestive heart failure
Q Feng, X Lu, AJ Fortin, A Pettersson… - Cardiovascular …, 1998 - academic.oup.com
Abstract Objective: NG, N G-dimethylarginine (asymmetric dimethylarginine, ADMA) is an
important endogenous substance with potent inhibitory actions on nitric oxide (NO) …
important endogenous substance with potent inhibitory actions on nitric oxide (NO) …
High plasma level of asymmetric dimethylarginine in patients with acutely exacerbated congestive heart failure: role in reduction of plasma nitric oxide level
M Saitoh, T Osanai, T Kamada, T Matsunaga… - Heart and vessels, 2003 - Springer
Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, is
elevated in congestive heart failure (CHF) concomitantly with the higher levels of nitric oxide …
elevated in congestive heart failure (CHF) concomitantly with the higher levels of nitric oxide …
Asymmetric dimethylarginine (ADMA) induces vascular endothelium impairment and aggravates post-ischemic ventricular dysfunction in rats
VDG Colonna, S Bonomo, P Ferrario, M Bianchi… - European journal of …, 2007 - Elsevier
Asymmetric dimethylarginine (ADMA) is an endogenous nitric oxide (NO) inhibitor
recognized as an independent risk factor for endothelial dysfunction and coronary heart …
recognized as an independent risk factor for endothelial dysfunction and coronary heart …
Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans
JT Kielstein, B Impraim, S Simmel, SM Bode-Böger… - Circulation, 2004 - Am Heart Assoc
Background—Increased blood concentrations of the endogenous nitric oxide synthase
(NOS) inhibitor asymmetrical dimethylarginine (ADMA) have been linked to excess …
(NOS) inhibitor asymmetrical dimethylarginine (ADMA) have been linked to excess …
Central and peripheral effects of asymmetric dimethylarginine, an endogenous nitric oxide synthetase inhibitor
JS Jin, LG D'Alecy - Journal of cardiovascular pharmacology, 1996 - journals.lww.com
We tested the hypothesis that the endogenous nitric oxide synthetase (NOS) inhibitor,
asymmetric dimethylarginine (ADMA), regulates cardiovascular function by central …
asymmetric dimethylarginine (ADMA), regulates cardiovascular function by central …
Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase
V Achan, M Broadhead, M Malaki… - … , and vascular biology, 2003 - Am Heart Assoc
Objective—Plasma levels of an endogenous nitric oxide (NO) synthase inhibitor, asymmetric
dimethylarginine (ADMA), are elevated in chronic renal failure, hypertension, and chronic …
dimethylarginine (ADMA), are elevated in chronic renal failure, hypertension, and chronic …
Effects of asymmetric dimethylarginine (ADMA) infusion in humans
JT Kielstein, D Tsikas, D Fliser - European Journal of Clinical …, 2006 - Springer
Increased blood concentrations of the endogenous nitric oxide synthase (NOS) inhibitor
asymmetric dimethylarginine (ADMA) can be found in patients with cardiovascular risk …
asymmetric dimethylarginine (ADMA) can be found in patients with cardiovascular risk …
Endothelin stimulates an endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine, in experimental heart failure
M Ohnishi, A Wada, T Tsutamoto, M Fujii, T Matsumoto… - 2002 - portlandpress.com
Congestive heart failure (CHF) is characterized by increased peripheral vascular resistance.
Endothelin-1 (ET-1), a potent endothelium-derived vasoconstrictor, is present at increased …
Endothelin-1 (ET-1), a potent endothelium-derived vasoconstrictor, is present at increased …
Role of asymmetric dimethylarginine for angiotensin II-induced target organ damage in mice
J Jacobi, R Maas, N Cordasic, K Koch… - American Journal …, 2008 - journals.physiology.org
The aim of the present study was to investigate the role of the endogenous nitric oxide
synthase inhibitor asymmetric dimethylarginine (ADMA) and its degrading enzyme …
synthase inhibitor asymmetric dimethylarginine (ADMA) and its degrading enzyme …
Elevated levels of asymmetric dimethylarginine in chronic heart failure: a pathophysiologic link between oxygen radical load and impaired vasodilator capacity and the …
S Von Haehling, SM Bode‐Böger… - Clinical …, 2010 - Wiley Online Library
Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide–dependent
vasodilation. In 113 patients with chronic heart failure (CHF) and 26 controls, ADMA level …
vasodilation. In 113 patients with chronic heart failure (CHF) and 26 controls, ADMA level …